SiRNA screen identifies QPCT as a druggable target for Huntington's disease

Nature Chemical Biology

Volumn 11, Issue 5, 2015, Pages 347-354

  Jimenez Sanchez, Maria ^a   Lam, Wun ^a,b   Hannus, Michael ^c   Sönnichsen, Birte ^c   Imarisio, Sara ^a,b   Fleming, Angeleen ^a,b   Tarditi, Alessia ^d,g   Menzies, Fiona ^a   Ed Dami, Teresa ^a,b,h   Xu, Catherine ^a,b   Gonzalez Couto, Eduardo ^d,i   Lazzeroni, Giulia ^d   Heitz, Freddy ^d,j   Diamanti, Daniela ^d   Massai, Luisa ^d   Satagopam, Venkata P ^e,f   Marconi, Guido ^d,k   Caramelli, Chiara ^d,l   Nencini, Arianna ^d   Andreini, Matteo ^d,m   Sardone, Gian Luca ^d   Caradonna, Nicola P ^d   Porcari, Valentina ^d   Scali, Carla ^d   Schneider, Reinhard ^e,f   Pollio, Giuseppe ^d   O'Kane, Cahir J ^b   Caricasole, Andrea ^d,m   Rubinsztein, David C ^a   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Cenix BioScience GmbH   (Germany)

^d Siena Biotech SpA   (Italy)

^e EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^f UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^g Research Institute of the Free State of Bavaria   (Germany)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ PerkinElmer Informatics   (Spain)

^j GENKYOTEX SA   (Switzerland)

^k Autifony Srl ^*  (Italy)

^l NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^m IRBM   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CRYSTALLIN; AMINOACYLTRANSFERASE; ENHANCED GREEN FLUORESCENT PROTEIN; ENZYME INHIBITOR; GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE; GREEN FLUORESCENT PROTEIN; HTT PROTEIN, HUMAN; NERVE PROTEIN; SMALL INTERFERING RNA;

ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGY; C57BL MOUSE; CELL CULTURE; DIAGNOSTIC USE; DROSOPHILA; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; HUNTINGTON DISEASE; METABOLISM; MOUSE; MUTATION; NERVE CELL; ZEBRA FISH;

ALPHA-CRYSTALLIN B CHAIN; AMINOACYLTRANSFERASES; ANIMALS; CELLS, CULTURED; COMPUTATIONAL BIOLOGY; DROSOPHILA; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GREEN FLUORESCENT PROTEINS; HUMANS; HUNTINGTON DISEASE; MICE; MICE, INBRED C57BL; MUTATION; NERVE TISSUE PROTEINS; NEURONS; RNA, SMALL INTERFERING; ZEBRAFISH;

EID: 84932081512     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1790     Document Type: Article

References (57)

1. Imarisio, S. et al. Huntington's disease: from pathology and genetics to potential therapies. Biochem. J. 412, 191-209 (2008).
2. Zuccato, C., Valenza, M., Cattaneo, E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 90, 905-981 (2010).
3. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72, 971-983 (1993).
4. Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506 (1996).
5. Hodgson, J.G. et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23, 181-192 (1999).
6. Soto, C., Estrada, L.D. Protein misfolding and neurodegeneration. Arch. Neurol. 65, 184-189 (2008).
7. Takahashi, T. et al. Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum. Mol. Genet. 17, 345-356 (2008).
8. Lajoie, P., Snapp, E.L. Formation and toxicity of soluble polyglutamine oligomers in living cells. PLoS ONE 5, e15245 (2010).
9. Hartl, F.U., Bracher, A., Hayer-Hartl, M. Molecular chaperones in protein folding and proteostasis. Nature 475, 324-332 (2011).
10. Sathasivam, K. et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc. Natl. Acad. Sci. USA 110, 2366-2370 (2013).
11. Bleicher, K.H., Böhm, H.-J., Müller, K., Alanine, A.I. Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov. 2, 369-378 (2003).
12. Li, M., Huang, Y., Ma, A.A.K., Lin, E., Diamond, M.I. Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice. Neurobiol. Dis. 36, 413-420 (2009).
13. Marsh, J.L. et al. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum. Mol. Genet. 9, 13-25 (2000).
14. Dietzl, G. et al. A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature 448, 151-156 (2007).
15. Schilling, S. et al. Isolation and characterization of glutaminyl cyclases from Drosophila: evidence for enzyme forms with different subcellular localization. Biochemistry 46, 10921-10930 (2007).
16. Jackson, G.R. et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 21, 633-642 (1998).
17. Franceschini, N., Kirschfeld, K. Pseudopupil phenomena in the compound eye of Drosophila. Kybernetik 9, 159-182 (1971).
18. Ravikumar, B. et al. Dynein mutations impair autophagic clearance of aggregate-prone proteins. Nat. Genet. 37, 771-776 (2005).
19. Zhang, S., Binari, R., Zhou, R., Perrimon, N. A genomewide RNA interference screen for modifiers of aggregates formation by mutant Huntingtin in Drosophila. Genetics 184, 1165-1179 (2010).
20. Wyttenbach, A. et al. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA 97, 2898-2903 (2000).
21. Cynis, H. et al. Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. Biochim. Biophys. Acta 1764, 1618-1625 (2006).
22. Saido, T.C. Involvement of polyglutamine endolysis followed by pyroglutamate formation in the pathogenesis of triplet repeat/polyglutamine-expansion diseases. Med. Hypotheses 54, 427-429 (2000).
23. Onodera, O. et al. Oligomerization of expanded-polyglutamine domain fluorescent fusion proteins in cultured mammalian cells. Biochem. Biophys. Res. Commun. 238, 599-605 (1997).
24. Rankin, J., Wyttenbach, A., Rubinsztein, D.C. Intracellular green fluorescent protein-polyalanine aggregates are associated with cell death. Biochem. J. 348, 15-19 (2000).
25. Luo, S., Mizuta, H., Rubinsztein, D.C. p21-activated kinase 1 promotes soluble mutant huntingtin self-interaction and enhances toxicity. Hum. Mol. Genet. 17, 895-905 (2008).
26. Buchholz, M. et al. The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship. J. Med. Chem. 49, 664-677 (2006).
27. Schilling, S. et al. Glutaminyl cyclase inhibition attenuates pyroglutamate A? and Alzheimer's disease-like pathology. Nat. Med. 14, 1106-1111 (2008).
28. Schilling, S. et al. Continuous spectrometric assays for glutaminyl cyclase activity. Anal. Biochem. 303, 49-56 (2002).
29. Yoon, S., Welsh, W.J. Identification of a minimal subset of receptor conformations for improved multiple conformation docking and two-step scoring. J. Chem. Inf. Comput. Sci. 44, 88-96 (2004).
30. Polgár, T., Keserü, G.M. Ensemble docking into flexible active sites. Critical evaluation of FlexE against JNK-3 and ?-secretase. J. Chem. Inf. Model. 46, 1795-1805 (2006).
31. Huang, K.-F., Liu, Y.-L., Cheng, W.-J., Ko, T.-P., Wang, A.H.-J. Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation. Proc. Natl. Acad. Sci. USA 102, 13117-13122 (2005).
32. Huang, K.-F. et al. Structures of human Golgi-resident glutaminyl cyclase and its complexes with inhibitors reveal a large loop movement upon inhibitor binding. J. Biol. Chem. 286, 12439-12449 (2011).
33. Ruiz-Carrillo, D. et al. Structures of glycosylated mammalian glutaminyl cyclases reveal conformational variability near the active center. Biochemistry 50, 6280-6288 (2011).
34. Jones, G., Willett, P., Glen, R.C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 245, 43-53 (1995).
35. Jones, G., Willett, P., Glen, R.C., Leach, A.R., Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267, 727-748 (1997).
36. Verdonk, M.L., Cole, J.C., Hartshorn, M.J., Murray, C.W., Taylor, R.D. Improved protein-ligand docking using GOLD. Proteins 52, 609-623 (2003).
37. Palm, K., Luthman, K., Ros, J., Grasjo, J., Artursson, P. Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. J. Pharmacol. Exp. Ther. 291, 435-443 (1999).
38. Song, H. et al. Inhibition of glutaminyl cyclase ameliorates amyloid pathology in an animal model of Alzheimer's disease via the modulation of ?-secretase activity. J. Alzheimers Dis. 43, 797-807 (2014).
39. Robertson, A.L. et al. Small heat-shock proteins interact with a flanking domain to suppress polyglutamine aggregation. Proc. Natl. Acad. Sci. USA 107, 10424-10429 (2010).
40. Bilen, J., Bonini, N.M. Drosophila as a model for human neurodegenerative disease. Annu. Rev. Genet. 39, 153-171 (2005).
41. Tue, N.T., Shimaji, K., Tanaka, N., Yamaguchi, M. Effect of ?B-crystallin on protein aggregation in Drosophila. J. Biomed. Biotechnol. 2012, 252049 (2012).
42. Williams, A. et al. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat. Chem. Biol. 4, 295-305 (2008).
43. Lejeune, F.-X. et al. Large-scale functional RNAi screen in C. elegans identifies genes that regulate the dysfunction of mutant polyglutamine neurons. BMC Genomics 13, 91 (2012).
44. Miller, J.P. et al. Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. Neuron 67, 199-212 (2010).
45. Miller, J.P. et al. A genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's disease. PLoS Genet. 8, e1003042 (2012).
46. Yamanaka, T. et al. Large-scale RNA interference screening in mammalian cells identifies novel regulators of mutant huntingtin aggregation. PLoS ONE 9, e93891 (2014).
47. Waudby, C.A. et al. The interaction of ?B-crystallin with mature ?-synuclein amyloid fibrils inhibits their elongation. Biophys. J. 98, 843-851 (2010).
48. Raman, B. et al. ?B-crystallin, a small heat-shock protein, prevents the amyloid fibril growth of an amyloid ?-peptide and ?2-microglobulin. Biochem. J. 392, 573-581 (2005).
49. Hochberg, G.K.A. et al. The structured core domain of ?B-crystallin can prevent amyloid fibrillation and associated toxicity. Proc. Natl. Acad. Sci. USA 111, E1562-E1570 (2014).
50. Freeman, M. Reiterative use of the EGF receptor triggers differentiation of all cell types in the Drosophila eye. Cell 87, 651-660 (1996).
51. Narain, Y., Wyttenbach, A., Rankin, J., Furlong, R.A., Rubinsztein, D.C. A molecular investigation of true dominance in Huntington's disease. J. Med. Genet. 36, 739-746 (1999).
52. D'Agostino, M. et al. The cytosolic chaperone ?-crystallin B rescues folding and compartmentalization of misfolded multispan transmembrane proteins. J. Cell Sci. 126, 4160-4172 (2013).
53. Renna, M., Caporaso, M.G., Bonatti, S., Kaufman, R.J., Remondelli, P. Regulation of ERGIC-53 gene transcription in response to endoplasmic reticulum stress. J. Biol. Chem. 282, 22499-22512 (2007).
54. Howarth, J.L. et al. Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion formation in models of polyglutamine disease. Mol. Ther. 15, 1100-1105 (2007).
55. Westerfield, M. The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (Danio rerio) (University of Oregon Press, 1995).
56. Kimmel, C.B., Ballard, W.W., Kimmel, S.R., Ullmann, B., Schilling, T.F. Stages of embryonic development of the zebrafish. Dev. Dyn. 203, 253-310 (1995).
57. Hyatt, G.A., Schmitt, E.A., Fadool, J.M., Dowling, J.E. Retinoic acid alters photoreceptor development in vivo. Proc. Natl. Acad. Sci. USA 93, 13298-13303 (1996).